Key result
Aspirin therapy at 4 or 40 mg/kg per day reduced ADP-stimulated platelet aggregation in non-diabetic rats but was ineffective in streptozotocin-diabetic rats.
Why the study?
Does chronic hyperglycemia interfere with the preventive effects of aspirin on platelet reactivity in rats?
Population
Non-diabetic and streptozotocin-diabetic rats
Comparison
Aspirin 4 or 40 mg/kg per day orally for 8 weeks vs Non-diabetic rats treated with the same doses of…
Design
Preclinical
Follow-up
8 weeks
Authors
Loading...
Reduced aspirin efficacy in diabetic rats; hypothesis-generating for impaired effects in human diabetes, needing clinical studies.
Does chronic hyperglycemia interfere with the preventive effects of aspirin on platelet reactivity in rats?
Chronic hyperglycemia in a diabetic rat model impairs the antiplatelet efficacy of aspirin, likely due to reduced vulnerability of platelet proteins to aspirin-induced acetylation.
Watała et al. (2006) studied Experimental diabetes. Aspirin (ASA) vs. Non-diabetic control rats was evaluated on ADP-stimulated platelet aggregation. Aspirin therapy at 4 or 40 mg/kg per day reduced ADP-stimulated platelet aggregation in non-diabetic rats but was ineffective in streptozotocin-diabetic rats.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: